Bio Rad’s line of RT-qPCR instruments and reagents provides the research community with needed tools for complex genetic analysis. From single target detection with the MyiQ™ Real-Time PCR System, to ...

Bio-Rad Laboratories, Inc. has announced the availability of its iScript™ RT-qPCR Sample Preparation Reagent for rapid isolation of total RNA and enabling reverse transcription and real-time PCR to be ...

HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO and BIO.B), a life sciences company with a market capitalization of $6.8 billion and strong financial health according to InvestingPro data, ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading Korean developer of ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...